These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 24228714)

  • 1. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
    Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
    J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in melatonin receptor ligands.
    Zlotos DP
    Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sites and mechanisms of action of melatonin in mammals: the MT1 and MT2 receptors].
    Schuster C
    J Soc Biol; 2007; 201(1):85-96. PubMed ID: 17762828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
    Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
    Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homology modeling of MT1 and MT2 receptors.
    Farce A; Chugunov AO; Logé C; Sabaouni A; Yous S; Dilly S; Renault N; Vergoten G; Efremov RG; Lesieur D; Chavatte P
    Eur J Med Chem; 2008 Sep; 43(9):1926-44. PubMed ID: 18255198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression.
    Boiko DI; Shkodina AD; Hasan MM; Bardhan M; Kazmi SK; Chopra H; Bhutra P; Baig AA; Skrypnikov AM
    Neurochem Res; 2022 Oct; 47(10):2909-2924. PubMed ID: 35689787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of melatonin ligands.
    Delagrange P; Boutin JA
    Chronobiol Int; 2006; 23(1-2):413-8. PubMed ID: 16687314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of the ligand binding and signaling mechanism of melatonin receptors.
    Wang Q; Lu Q; Guo Q; Teng M; Gong Q; Li X; Du Y; Liu Z; Tao Y
    Nat Commun; 2022 Jan; 13(1):454. PubMed ID: 35075127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XFEL structures of the human MT
    Johansson LC; Stauch B; McCorvy JD; Han GW; Patel N; Huang XP; Batyuk A; Gati C; Slocum ST; Li C; Grandner JM; Hao S; Olsen RHJ; Tribo AR; Zaare S; Zhu L; Zatsepin NA; Weierstall U; Yous S; Stevens RC; Liu W; Roth BL; Katritch V; Cherezov V
    Nature; 2019 May; 569(7755):289-292. PubMed ID: 31019305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep-wake characterization of double MT₁/MT₂ receptor knockout mice and comparison with MT₁ and MT₂ receptor knockout mice.
    Comai S; Ochoa-Sanchez R; Gobbi G
    Behav Brain Res; 2013 Apr; 243():231-8. PubMed ID: 23333399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.
    Roth T; Stubbs C; Walsh JK
    Sleep; 2005 Mar; 28(3):303-7. PubMed ID: 16173650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photoperiodic regulation of MT1 and MT2 melatonin receptor expression in spleen and thymus of a tropical rodent Funambulus pennanti during reproductively active and inactive phases.
    Ahmad R; Haldar C
    Chronobiol Int; 2010 May; 27(3):446-62. PubMed ID: 20524795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin receptors in the eye: location, second messengers and role in ocular physiology.
    Alarma-Estrany P; Pintor J
    Pharmacol Ther; 2007 Mar; 113(3):507-22. PubMed ID: 17229466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A novel therapeutic drug: ramelteon].
    Miyamoto M
    Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin receptor type 1 signals to extracellular signal-regulated kinase 1 and 2 via Gi and Gs dually coupled pathways in HEK-293 cells.
    Chen L; He X; Zhang Y; Chen X; Lai X; Shao J; Shi Y; Zhou N
    Biochemistry; 2014 May; 53(17):2827-39. PubMed ID: 24724723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are G protein-coupled receptor heterodimers of physiological relevance?--Focus on melatonin receptors.
    Levoye A; Jockers R; Ayoub MA; Delagrange P; Savaskan E; Guillaume JL
    Chronobiol Int; 2006; 23(1-2):419-26. PubMed ID: 16687315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional MT1 and MT2 melatonin receptors in mammals.
    Dubocovich ML; Markowska M
    Endocrine; 2005 Jul; 27(2):101-10. PubMed ID: 16217123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.
    Hu Y; Chan KH; He X; Ho MK; Wong YH
    PLoS One; 2014; 9(12):e113638. PubMed ID: 25479338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
    Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
    Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.